ATE519504T1 - Chromatin-remodellierende substanzen zur erhöhung der expression von pdx-1 und förderung der zelldifferenzierung - Google Patents

Chromatin-remodellierende substanzen zur erhöhung der expression von pdx-1 und förderung der zelldifferenzierung

Info

Publication number
ATE519504T1
ATE519504T1 AT06254532T AT06254532T ATE519504T1 AT E519504 T1 ATE519504 T1 AT E519504T1 AT 06254532 T AT06254532 T AT 06254532T AT 06254532 T AT06254532 T AT 06254532T AT E519504 T1 ATE519504 T1 AT E519504T1
Authority
AT
Austria
Prior art keywords
pdx
substances
cell differentiation
promote cell
increase expression
Prior art date
Application number
AT06254532T
Other languages
English (en)
Inventor
Janet E Davis
Ramie Fung
Original Assignee
Lifescan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifescan Inc filed Critical Lifescan Inc
Application granted granted Critical
Publication of ATE519504T1 publication Critical patent/ATE519504T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06254532T 2005-08-31 2006-08-31 Chromatin-remodellierende substanzen zur erhöhung der expression von pdx-1 und förderung der zelldifferenzierung ATE519504T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71307205P 2005-08-31 2005-08-31

Publications (1)

Publication Number Publication Date
ATE519504T1 true ATE519504T1 (de) 2011-08-15

Family

ID=37806561

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06254532T ATE519504T1 (de) 2005-08-31 2006-08-31 Chromatin-remodellierende substanzen zur erhöhung der expression von pdx-1 und förderung der zelldifferenzierung

Country Status (6)

Country Link
EP (1) EP1949916B1 (de)
JP (1) JP2007061096A (de)
AT (1) ATE519504T1 (de)
AU (1) AU2006204630A1 (de)
CA (1) CA2557635C (de)
ES (1) ES2369240T3 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009127719A1 (en) * 2008-04-18 2009-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for obtaining ngn3-expressing cells and insulin producing-beta cells
JP5294041B2 (ja) * 2008-06-27 2013-09-18 独立行政法人産業技術総合研究所 膵臓疾患又は糖尿病のための膵臓細胞再生移植用キット
WO2011118211A1 (ja) * 2010-03-23 2011-09-29 株式会社クラレ 多能性哺乳細胞を分化させる培養方法
CA3012929C (en) 2012-07-31 2023-01-17 The Board Of Regents Of The University Of Texas System Methods and compositions for in vivo induction of pancreatic beta cell formation
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
US11370823B2 (en) 2014-10-29 2022-06-28 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
KR101697437B1 (ko) 2015-10-12 2017-01-17 전남대학교병원 중간엽줄기세포의 심근유사세포 분화유도용 아피시딘 함유 조성물
WO2019148067A1 (en) 2018-01-26 2019-08-01 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
EP4410958A4 (de) * 2021-09-30 2025-11-12 Jsr Corp Organoidherstellungsverfahren, kulturmedium zur organoidherstellung, organoid und testsubstanzbeurteilungsverfahren

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774120B1 (en) * 1999-06-01 2004-08-10 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US20040002447A1 (en) * 2002-06-04 2004-01-01 Regents Of The University Of California Induction of insulin expression

Also Published As

Publication number Publication date
ES2369240T3 (es) 2011-11-28
HK1118719A1 (en) 2009-02-20
EP1949916A1 (de) 2008-07-30
CA2557635A1 (en) 2007-02-28
CA2557635C (en) 2014-10-28
JP2007061096A (ja) 2007-03-15
EP1949916B1 (de) 2011-08-10
AU2006204630A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
ATE474592T1 (de) Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz
NL301145I2 (nl) Tirbanibulin
IS3013B (is) Meltikornatálmar og aðferðir til að nota þá
DE602007011908D1 (de) Verwendung von gpr119-rezeptoragonisten zur vermehrung der knochenmasse und zur behandlung von osteoporose sowie kombinationstherapie dafür
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
EA200870164A1 (ru) Лечение вирусного гепатита
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
PH12014500053A1 (en) Proteasome inhibitors
IL184403A0 (en) Method and composition for treating mammalian diseases and injuries caused by the over expression of peroxynitrite
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
DE602005011656D1 (de) Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin
DE602005023877D1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
ATE519504T1 (de) Chromatin-remodellierende substanzen zur erhöhung der expression von pdx-1 und förderung der zelldifferenzierung
ATE529404T1 (de) Phenoxyessigsäuren als ppar-delta-aktivatoren
DE602006010400D1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
AR059193A1 (es) Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
ATE399158T1 (de) Heterocyclische phenylaminopropanolderivate als modulatoren der monoaminwiederaufnahme zur behandlung von vasomotorischen symptomen (vms)
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
EP1759020A4 (de) Acacs als modifikatoren des igf-weges und verwendungsverfahren
ATE487692T1 (de) Verfahren und verbindungen zum nachweis von medizinischen erkrankungen
ATE425755T1 (de) 4-aminophenyl-morpholinon-derivate zur behandlung von hepatitis c
EA201791835A3 (ru) Ингибиторы протеасом

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1949916

Country of ref document: EP